FDA Approves Eli Lilly's Oral GLP-1 Drug Foundayo

The FDA approved Foundayo, Eli Lilly's oral GLP-1 obesity treatment containing orforglipron. In the ATTAIN-1 Phase 3 trial, patients at the highest dose achieved an average weight loss of 12 pounds. As the first once-daily oral GLP-1 requiring no dietary restrictions, Foundayo reshapes the obesity treatment market.